An Appeal To The Global Health Community For A Tripartite Innovation: An "Essential Diagnostics List," "Health In All Policies," And "See-Through 21(St) Century Science And Ethics"
Göster/ Aç
Tarih
2015Yazar
Dove, Edward S.
Barlas, I. Omer
Birch, Kean
Boehme, Catharina
Borda-Rodriguez, Alexander
Byne, William M.
Chaverneff, Florence
Coskun, Yavuz
Dahl, Marja-Liisa
Dereli, Turkay
Diwakar, Shyam
Elbeyli, Levent
Endrenyi, Laszlo
Eroglu-Kesim, Belgin
Ferguson, Lynnette R.
Gungor, Kivanc
Gursoy, Ulvi
Hekim, Nezih
Huzair, Farah
Kaushik, Kabeer
Kickbusch, Ilona
Kiroglu, Olcay
Kolker, Eugene
Kononen, Eija
Lin, Biaoyang
Llerena, Adrian
Malhan, Faruk
Nair, Bipin
Patrinos, George P.
Sardas, Semra
Sert, Ozlem
Srivastava, Sanjeeva
Steuten, Lotte M. G.
Toraman, Cengiz
Vayena, Effy
Wang, Wei
Warnich, Louise
Ozdemir, Vural
Üst veri
Tüm öğe kaydını gösterÖzet
Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for promulgating an "Essential Diagnostics List." Additionally, we explain the ways in which adopting a vision for "Health in All Policies" could link essential diagnostics with robust and timely societal outcomes such as sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First, we propose the need for a new, "see through" taxonomy for knowledge-based innovation as we transition from the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20(th) century to the anticipated knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods, quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory focus on innovation is crucial and applicable across all sectors, including public, private, or public-private partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values, and social systems. By making the value systems embedded in scientific design and knowledge co-production transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global health community to consider the necessary qualities of good governance for 21st century organizations that will embark on developing essential diagnostics. These have importance not only for science and knowledge-based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today and for future generations.